ShorT and OPtimal duration of Dual AntiPlatelet Therapy study

ShorT and OPtimal duration of Dual AntiPlatelet Therapy study - STOPDAPT

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008878

Enrollment

1500

Registered

2012-09-15

Start date

2012-09-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary artery disease

Interventions

discontinuation of Thienopyridine at 3moths after stent implantation

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who received PCI using everolimus-eluting cobalt-chromium stent (Xience Prime)

Exclusion criteria

Exclusion criteria: Patients who have been implanted drug eluting stent other than everolimus-eluting cobalt-chromium stent.

Design outcomes

Primary

Measure	Time frame
composite endpoint of cardiovascular death in 12 months, myocardial infarction (MI), stroke (ischemic and hemorrhagic), stent thrombosis (Definite stent thrombosis [ST] not resulting in MI) and serious bleeding (TIMI Major/Minor).	—

Secondary

Measure	Time frame
[major secondary endpoint] Cardiovascular death/ MI/ stroke/ definite ST Major bleeding (TIMI Major/ Minor) [secondary endpoint] Death / MI Death Cardiovascular death/ MI Cardiovascular death MI Stroke ST (ARC definition) TLF TVF MACE Any TLR Clinically-driven TLR Non-TLR CABG Any TVR Any revascularization Bleeding complications	—

Countries

Japan

Contacts

Public ContactMasahiro Natsuaki

Kyoto University Hospital Department of cardiovascular medicine

075-751-4255

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026